Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

May 30, 2017

Primary Completion Date

July 12, 2018

Study Completion Date

November 14, 2018

Conditions
Psoriasis
Interventions
DRUG

Spesolimab (low dose)

12 weeks treatment

DRUG

Placebo

12 weeks treatment

DRUG

Spesolimab (high dose)

12 weeks treatment

Trial Locations (18)

2400

Bispebjerg og Frederiksberg Hospital, København NV

2900

Gentofte Hospital, Hellerup

8200

Aarhus University Hospital, Skejby, Aarhus

10117

Charité - Universitätsmedizin Berlin, Berlin

20537

TFS Trial Form Support GmbH, Hamburg

24105

Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel

28031

Hospital Universitario Infanta Leonor, Madrid

28034

Hospital Ramón y Cajal, Madrid

60596

Universitätsklinikum Frankfurt, Frankfurt am Main

69120

Universitätsklinikum Heidelberg, Heidelberg

E3B 1G9

Dr. Irina Turchin PC Inc., Fredericton

L4C 9M7

York Dermatology Clinic and Research Centre, Richmond Hill

H2K 4L5

Innovaderm Research Inc., Montreal

09124

Ospedale San Giovanni di Dio, Cagliari

00133

Pol. Universitario Tor Vergata, Roma

08026

Hospital Santa Creu i Sant Pau, Barcelona

413 45

Sahlgrenska US, Göteborg, Gothenburg

171 76

Karolinska Univ. sjukhuset, Stockholm

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY